Stock Events

Stock Events

Adaptimmune Therapeutics 

$0.03
0
+$0+0% Today

Statistics

Day High
0.03
Day Low
0.03
52W High
0.62
52W Low
0
Volume
117,624
Avg. Volume
4,758,567
Mkt Cap
44.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-39.78%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
356.06MRevenue
-141.63MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ADAPY. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is involved in the development of cellular therapy products for cancer, directly competing with Adaptimmune's focus on T-cell therapy for cancer treatment.
Novartis
NVS
Mkt Cap237.61B
Novartis is a major player in the CAR-T cell therapy market with its approved products, competing with Adaptimmune's focus on similar cancer treatments.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is focused on the development of allogeneic CAR-T therapies, which could compete with Adaptimmune's autologous T-cell therapy approach.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad oncology portfolio, including investments in immunotherapies that could compete with Adaptimmune's T-cell based therapies.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is heavily involved in cancer immunotherapy with its blockbuster drug Keytruda and is expanding into cellular therapies, potentially competing with Adaptimmune.

About

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Show more...
CEO
Mr. Adrian G. Rawcliffe
Employees
506
Country
GB
ISIN
US00653A1079

Listings

OTCM
US
ADAPY

0 Comments

Share your thoughts

FAQ

What is Adaptimmune Therapeutics stock price today?▼
The current price of ADAPY is $0.03 USD — it has increased by +0% in the past 24 hours. Watch Adaptimmune Therapeutics stock price performance more closely on the chart.
What is Adaptimmune Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adaptimmune Therapeutics stocks are traded under the ticker ADAPY.
What is Adaptimmune Therapeutics market cap?▼
Today Adaptimmune Therapeutics has the market capitalization of 44.53M
What is Adaptimmune Therapeutics revenue for the last year?▼
Adaptimmune Therapeutics revenue for the last year amounts to 356.06M USD.
What is Adaptimmune Therapeutics net income for the last year?▼
ADAPY net income for the last year is -141.63M USD.
How many employees does Adaptimmune Therapeutics have?▼
As of February 04, 2026, the company has 506 employees.
In which sector is Adaptimmune Therapeutics located?▼
Adaptimmune Therapeutics operates in the Health Care sector.
When did Adaptimmune Therapeutics complete a stock split?▼
Adaptimmune Therapeutics has not had any recent stock splits.
Where is Adaptimmune Therapeutics headquartered?▼
Adaptimmune Therapeutics is headquartered in Abingdon, GB.